Efficacy and Safety of IL-6 Inhibitors in Patients with COVID-19 Pneumonia: A Systematic Review and Meta-Analysis of Multicentre, Randomised Trials
Abstract
Introduction: The novel coronavirus disease 2019 (COVID-19) is frequently characterized by dysregulated host immune response with hyperinflammation and self-induced host inflammatory damage that results in severe respiratory failure and frequently death. Interleukin-6 (IL-6) appeared among the key cytokines involved in COVID-19 associated cytokine storm. Therefore, several trials investigated whether IL-6 inhibition with tocilizumab or sarilumab could improve symptoms and outcome of COVID-19 patients. We performed a meta-analysis of randomized trials to test this hypothesis.
Methods: PubMed, Scopus, Cochrane central register and medRxiv were searched by two independent investigators up to February 23rd, 2021. Inclusion criteria were: administration of tocilizumab or sarilumab, COVID-19 pneumonia, randomized controlled trials. Studies in setting other than adult human COVID-19 were excluded. The primary outcome was mortality at the longest follow-up available. Secondary outcomes included need for intubation and incidence of adverse events. Two independent investigators examined and extracted data from eligible trials.
Results: A total of 371 studies were assessed, with a total of 10 studies (6,465 patients) finally included in the meta-analysis. All the trials were multicentre and the majority were open-label vs standard treatment. IL-6 inhibitors use was associated with reduced all-cause mortality at the longest follow-up available (823/3,310 [24·9%] in the IL-6 inhibitors…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 6,465 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.